G6PD and acute myeloid leukemia: The PPP was also identified as a prosurvival pathway in AML cells with high mammalian target of rapamycin complex 1 (mTORC1) activity and inhibition of glucose-6-phosphate dehydrogenase (G6PD), the first rate-limiting enzyme of the oxidative arm of the PPP, selectively targeted AML cells [62].